XOMAO

XOMA Investors Have the Opportunity to Join Investigation of XOMA Royalty Corporation with the Schall Law Firm

04/28 05:40 pm

Halper Sadeh LLC is Investigating Whether OGN, XOMA, RMAX, SLNO are Obtaining Fair Deals for their Shareholders

04/27 09:23 pm

Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million

04/27 01:18 pm

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of XOMA Royalty Corporation (NASDAQ: XOMA)

04/27 10:58 am

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Miluna Acquisition Corp. (NASDAQ: MMTX)

04/27 10:55 am

Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator

04/27 07:00 am

XOMA Royalty Declares Quarterly Preferred Stock Dividends

03/18 04:30 pm

XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements

03/18 06:00 am

XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.

02/09 10:53 am

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA

01/20 05:47 pm

XOMA Royalty Declares Quarterly Preferred Stock Dividends

12/22 08:30 am

XOMA Royalty Enters into Agreement to Acquire Generation Bio

12/15 06:00 pm

Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition

12/05 08:45 am

Mural Oncology Announces Sanction of the Scheme by the High Court

12/03 05:30 pm

Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty

11/26 10:00 am

Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty

10/24 04:25 pm

XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement

10/17 11:45 am

XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.

10/02 04:43 pm

XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.

10/02 04:43 pm

Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and Extraordinary General Meeting

09/23 07:52 pm

XOMA Royalty Declares Quarterly Preferred Stock Dividends

09/22 07:30 am

XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.

09/17 09:00 am

XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right

08/04 07:30 am

HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right

08/04 07:00 am

$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Turnstone Biologics Corp. (NASDAQ: TSBX)

06/30 06:14 pm

XOMA Royalty Declares Quarterly Preferred Stock Dividends

06/18 07:30 am

XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million

05/27 08:01 am

XOMA Royalty Declares Quarterly Preferred Stock Dividends

03/20 07:30 am

XOMA Royalty Declares Quarterly Preferred Stock Dividends

12/19 08:30 am

XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio

12/02 08:30 am

XOMA Corp to rebrand as XOMA Royalty Corporation By Investing.com - Investing.com

07/09 11:12 am

XOMA Corporation: A Hold Rating With Steady Income From Preferred Shares

06/29 02:31 am

XOMA Declares Quarterly Preferred Stock Dividends

06/20 07:30 am

XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher

06/12 07:30 am

XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ

05/14 07:30 am

XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%

04/30 07:30 am

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

04/25 07:30 am

XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.

03/19 04:05 pm

XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value

03/08 08:30 am

XOMA to Present at Upcoming Investor Conferences in March

02/28 08:30 am

XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right

02/16 09:00 am

XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition

01/18 09:30 am

FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx

01/11 05:05 pm

XOMA Announces Stock Repurchase Program of up to $50 Million

01/02 08:30 am

XOMA Declares Quarterly Preferred Stock Dividends

12/20 08:30 am

I'm Buying Preferred Stocks Hand Over Fist

12/15 09:30 am

XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value

11/07 08:30 am

XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

10/31 07:30 am

XOMA Declares Quarterly Preferred Stock Dividends

09/25 07:30 am

XOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference

09/06 07:30 am